XINHUA PHARM(000756)

Search documents
新华制药(000756) - 2017 Q4 - 年度财报
2018-03-25 16:00
Financial Performance - The company's operating revenue for 2017 was CNY 4,515,716,784.19, representing a 12.47% increase compared to CNY 4,014,963,065.74 in 2016[13] - The total profit for 2017 reached CNY 268,173,876.00, a significant increase of 67.64% from CNY 159,968,492.21 in the previous year[13] - Net profit attributable to shareholders was CNY 221,248,751.89, marking a 66.29% increase from CNY 133,047,273.87 in 2016[13] - Basic earnings per share for 2017 were CNY 0.45, reflecting a 66.67% increase from CNY 0.27 in 2016[13] - The company's revenue for the year ended December 31, 2017, was RMB 4,515.717 million, an increase of 12.47% compared to 2016[114] - The net profit attributable to shareholders for the same period was RMB 209.592 million, representing a growth of 71.42% year-on-year, with basic earnings per share of RMB 0.45[114] Assets and Liabilities - The company's total assets increased by 11.66% to CNY 5,273,647,124.63 at the end of 2017, up from CNY 4,722,785,963.84 in 2016[13] - The net assets attributable to shareholders rose by 24.72% to CNY 2,480,023,776.59, compared to CNY 1,988,419,824.33 in 2016[13] - As of December 31, 2017, the total liabilities of the group amounted to RMB 2,694,194 thousand, an increase of 1.92% compared to the beginning of the year[134] - The asset-liability ratio stands at 51.09%[149] Cash Flow - The net cash flow from operating activities for 2017 was CNY 389,971,809.35, a decrease of 11.24% from CNY 439,348,332.79 in 2016[13] - The net cash increase from operating activities was RMB 389,972 thousand, with a significant difference from the net profit of RMB 221,249 thousand mainly due to fixed asset depreciation expenses[135] Shareholder Information - The company plans to distribute a cash dividend of CNY 0.50 per 10 shares and to increase capital by converting 3 shares for every 10 shares held[6] - The company reported a total of 478,353,421 shares outstanding as of December 31, 2017, an increase from 457,312,830 shares in 2016[25] - The largest shareholder, Shandong Xinhua Pharmaceutical Group, held 32.94% of the shares, totaling 157,587,763 shares[25] - The number of shareholders increased from 23,313 at the end of 2017 to 28,835 by February 28, 2018[23] Research and Development - Research and development investment for the year was RMB 160 million, an increase of 47.85% compared to the previous year[116] - The company has prioritized investment in research and development to drive innovation and improve product efficacy[1] - The company aims to achieve the industrialization of four new products, including Eidaravone, in 2018[121] - The company plans to initiate 2-3 ANDA registrations in 2018 to enhance its product portfolio[121] Market and Sales Performance - The sales revenue from the raw materials segment reached RMB 1.96 billion, a year-on-year increase of 10.97%, with significant growth in key products like Ibuprofen and Levodopa[115] - The sales revenue from the formulation segment was RMB 1.98 billion, up 13.42% year-on-year, with strategic products achieving sales of RMB 199.9 million, a growth of 33.91%[115] - The company achieved export revenue of USD 20.8 million, a year-on-year increase of 4.7%[115] Corporate Governance - The management team is committed to maintaining high standards of corporate governance and transparency[1] - The company has strengthened its corporate governance and compliance with relevant laws and regulations during the reporting period[65] - The audit committee confirmed that the 2017 financial statements were prepared in accordance with accounting policies and accurately reflected the company's financial position as of December 31, 2017[61] - The audit committee received a standard unqualified opinion from the accounting firm on the 2017 financial report, indicating compliance with auditing standards[62] Employee Information - The total number of employees in the group as of December 31, 2017, was 6,384, with a total salary expenditure of RMB 435,814 thousand[53] - The annual remuneration for directors, supervisors, and senior management in 2017 amounted to RMB 10,698.8 thousand[50] - The company completed 63 training projects in 2017, training 3,500 participants, and sent 177 individuals for external training[55] Environmental Responsibility - The total wastewater discharge from the main plant is less than 500 mg/L for chemical oxygen demand and less than 250 mg/L for ammonia nitrogen[200] - The annual ammonia nitrogen discharge is projected to be less than 12 tons[200] - The total annual emissions of volatile organic compounds (VOCs) from the main plant are less than 140 tons[200] - The company has been recognized as an advanced energy-saving enterprise in Shandong Province and has passed the ISO14001 environmental management system audit, becoming the first domestic pharmaceutical company to achieve this[197] Strategic Initiatives - The company is focusing on expanding its market presence through strategic partnerships and acquisitions[1] - The company is exploring opportunities in international markets to diversify its revenue streams[1] - A new technology platform is being developed to streamline operations and improve efficiency[1] - The company plans to accelerate the implementation of its large formulation strategy and enhance marketing efforts to cultivate new growth points in 2018[119]
新华制药(000756) - 2017 Q3 - 季度财报
2017-10-30 16:00
Financial Performance - Total assets increased by 9.44% to CNY 5,168,691,022.39 compared to the end of the previous year[8] - Net assets attributable to shareholders increased by 10.87% to CNY 2,204,574,772.00 compared to the end of the previous year[8] - Operating revenue for the period was CNY 1,049,427,867.78, a 7.31% increase year-on-year[8] - Net profit attributable to shareholders increased by 54.45% to CNY 66,898,743.52 for the period[8] - Basic earnings per share rose by 66.67% to CNY 0.15[8] - The weighted average return on equity increased by 0.85 percentage points to 3.09%[8] - The net profit attributable to the parent company for the first nine months of 2017 was RMB 173,673,696.38, a 94.74% increase year-on-year, driven by expanded sales and operational efficiencies[19] - The total profit for the first nine months of 2017 was RMB 228,169,350.26, representing an 84.61% increase compared to the same period last year, largely due to market expansion and land reserve gains[19] Cash Flow and Financing - Cash flow from operating activities decreased by 19.84% to CNY 193,925,949.01 year-to-date[8] - The net cash flow from financing activities for the first nine months of 2017 was RMB 217,510,727.81, an increase of RMB 124,599,476.09 year-on-year, primarily from funds raised through a private placement[19] - The company completed a private placement of A-shares, issuing 21,040,591 shares at a price of RMB 11.15 per share, raising a total of RMB 234,602,589.65[20] - Short-term borrowings decreased by 59.34% to RMB 370,000,000.00 as of September 30, 2017, due to repayment of due borrowings[17] - The company's financial expenses for the first nine months of 2017 were RMB 60,886,505.96, a 39.88% increase year-on-year, mainly due to increased foreign exchange losses[18] Shareholder Information - The total number of shareholders at the end of the reporting period was 19,452[12] - The largest shareholder, Shandong Xinhua Pharmaceutical Group, holds 34.46% of the shares[12] Assets and Investments - As of September 30, 2017, the group's cash and cash equivalents amounted to RMB 794,835,336.46, an increase of 41.60% compared to the beginning of the year, primarily due to funds raised from a private placement of shares[17] - Accounts receivable as of September 30, 2017, reached RMB 474,427,867.54, up 38.16% year-to-date, attributed to expanded sales scale and payment terms not yet reached[17] - The group's construction in progress was RMB 428,753,634.81 as of September 30, 2017, reflecting a 56.24% increase year-to-date due to significant investments in new projects[17] - The deferred tax liabilities increased by 596.21% to RMB 8,314,311.71 as of September 30, 2017, influenced by changes in the fair value of available-for-sale financial assets[18] Governance and Compliance - There were no instances of non-compliant external guarantees, indicating sound governance practices[27] - The company reported no non-operational fund occupation by controlling shareholders or related parties, ensuring financial integrity[28] - There were no securities investments during the reporting period, reflecting a conservative investment strategy[24] - The company did not engage in derivative investments, maintaining a straightforward financial approach[25] - No research, communication, or interview activities were conducted during the reporting period, suggesting a focus on internal operations[26] Poverty Alleviation Efforts - The report did not provide specific metrics or outcomes related to poverty alleviation efforts, indicating a lack of detailed disclosure in this area[29] - There were no awards or recognitions mentioned in the poverty alleviation section, suggesting limited external validation of efforts[29] - The company has outlined future plans for poverty alleviation, although specific details were not disclosed[30]
新华制药(000756) - 2017 Q2 - 季度财报
2017-08-13 16:00
Financial Performance - The company's operating revenue for the first half of 2017 was RMB 2,403,274,161.26, representing a 20.25% increase compared to RMB 1,998,500,412.91 in the same period last year[11]. - The total profit for the period reached RMB 147,562,389.11, a significant increase of 117.37% from RMB 67,886,265.86 in the previous year[11]. - Net profit attributable to shareholders of the listed company was RMB 106,774,952.86, up 132.79% from RMB 45,867,145.68 year-on-year[11]. - The basic earnings per share increased to RMB 0.23, reflecting a 130.00% rise compared to RMB 0.10 in the same period last year[11]. - Operating profit for the first half of 2017 was RMB 129,907 thousand, an increase of 89.23% compared to the same period last year[48]. - The company reported a total comprehensive income of RMB 143,161,350.15, compared to RMB 39,276,692.30 in the previous period, reflecting a growth of 264.5%[86]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 4,997,677,442.42, a 5.82% increase from RMB 4,722,785,963.84 at the end of the previous year[11]. - The company's total liabilities increased by 5.04% to RMB 2,776,656,691.70 from RMB 2,643,478,538.19 at the end of the previous year[11]. - The debt-to-asset ratio stood at 55.56% as of June 30, 2017[45]. - Current liabilities decreased from RMB 2,270,506,636.21 at the beginning of the year to RMB 1,802,450,165.96, a reduction of approximately 20.6%[80]. - Non-current liabilities rose significantly from RMB 372,971,901.98 to RMB 974,206,525.74, an increase of about 160.8%[80]. Cash Flow - The net cash flow from operating activities was RMB 9,557,583.42, a decrease of 88.60% compared to RMB 83,830,656.73 in the same period last year[11]. - Cash flow from operating activities generated a net cash inflow of RMB 9,557,583.42, down from RMB 83,830,656.73 last year[90]. - Cash inflow from financing activities surged to RMB 1,096,000,000.00, compared to RMB 190,000,000.00 in the previous year, reflecting a growth of 476.8%[92]. - The net cash flow from investing activities was negative at RMB 105,972,232.92, worsening from a negative RMB 87,192,899.64 in the previous year[92]. Shareholder Information - As of June 30, 2017, the total number of shares was 457,312,830, with 99.998% being unrestricted shares[16]. - The top ten shareholders held a total of 34.46% and 32.56% of the shares, respectively, with Shandong Xinhua Pharmaceutical Group Co., Ltd. holding 157,587,763 shares[17]. - The company had a total of 21,582 shareholders, including 47 H-share shareholders and 21,535 A-share shareholders[16]. - The largest unrestricted shareholder, Shandong Xinhua Pharmaceutical Group Co., Ltd., held 157,587,763 shares, representing 34.46% of the total shares[19]. Research and Development - R&D investment reached RMB 96,515 thousand in the first half of 2017, up 141.39% year-on-year, reflecting the company's focus on enhancing development potential[49]. - The company has established partnerships with universities for research and development, including a postdoctoral research station and various collaborative projects[33]. Market and Sales Performance - The raw material drug segment generated revenue of RMB 1.05 billion, up 14.46%, while the formulation segment reached RMB 1.067 billion, growing by 23.57%[32]. - The sales revenue of the new product "Jiening" increased by approximately 60%, and "Baochang" sales doubled, with "Kuxin" and "Xindaluo" series sales growing by 20% and 25% respectively[32]. - International cooperation projects led to revenue of RMB 55.43 million from formulation exports and CMO collaborations, marking a growth of 200.4%[32]. Environmental and Compliance - The company has established three wastewater treatment facilities with a processing capacity of 12,000 tons per day, ensuring compliance with wastewater discharge standards[67]. - The total chemical oxygen demand (COD) emissions were reported at 1,050 tons per year, with no exceedance of the regulatory limits[66]. - The company has implemented various air pollution control technologies, including dual-pipe technology and closed-loop gas discharge systems, to minimize emissions of volatile organic compounds (VOCs)[69]. Corporate Governance - The company appointed Mr. Zheng Zhonghui as the deputy general manager on February 27, 2017[25]. - The company has appointed three independent non-executive directors, ensuring compliance with corporate governance standards[74]. - There were no changes in the controlling shareholder or actual controller during the reporting period[21]. Accounting Policies - The financial statements are prepared in accordance with the Chinese Accounting Standards and reflect the company's financial position accurately[111]. - The company has not made any changes to significant accounting policies or estimates in the first half of 2017[165][166].
新华制药(000756) - 2016 Q4 - 年度财报(更新)
2017-04-25 16:00
Financial Performance - In 2016, the company's operating revenue reached RMB 4,014,963,065.74, representing an increase of 11.62% compared to RMB 3,597,033,209.79 in 2015[11] - The net profit attributable to shareholders of the listed company was RMB 122,271,549.68, a significant increase of 47.20% from RMB 83,062,257.17 in the previous year[11] - The total assets of the company at the end of 2016 were RMB 4,722,785,963.84, reflecting a growth of 5.13% from RMB 4,492,122,436.63 at the end of 2015[11] - The company reported a net cash flow from operating activities of RMB 439,348,332.79, which is an increase of 26.02% compared to RMB 348,636,176.12 in 2015[11] - The basic earnings per share for 2016 were RMB 0.27, up 50.00% from RMB 0.18 in 2015[11] - The total profit for the year was RMB 159,968 thousand, up 35.88% from the previous year[114] - The company achieved a net operating cash flow of RMB 439,348 thousand, which is a 26.02% increase compared to the prior year[114] - The company's revenue for the year ended December 31, 2016, was RMB 4,014,963 thousand, an increase of 11.62% compared to 2015[113] - Net profit attributable to shareholders was RMB 122,272 thousand, representing a growth of 47.20% year-over-year[113] Shareholder Information - The total number of shareholders increased from 29,550 to 34,395, representing a growth of about 16.5%[18] - The largest shareholder, Shandong Xinhua Pharmaceutical Group Co., Ltd., holds 34.46% of the shares, totaling 157,587,763 shares[19] - The second-largest shareholder, Hong Kong Central Clearing Limited, holds 32.56% of the shares, totaling 148,883,698 shares, with a decrease of 4,000 shares during the reporting period[19] - The total number of shares outstanding remains at 457,312,830, with 99.998% being unrestricted shares[21] - The company has a controlling shareholder, Shandong Xinhua Pharmaceutical Group Co., Ltd., which is a state-owned enterprise with a registered capital of RMB 298.5 million[25] - The top ten shareholders account for a significant portion of the company's equity, with the top two shareholders alone holding over 67%[19] Corporate Governance - The company has established a strong governance framework with independent directors and supervisors to oversee its operations and strategic direction[32] - The company has maintained a stable leadership structure, with many executives having long tenures since the early 2000s, contributing to continuity in management[38] - The company has appointed several experienced professionals in key management positions, including Mr. Du Deping as General Manager and Mr. Xu Lie as Union Chairman[30] - The independent directors include Mr. Du Guanhua, who has been serving since March 2015, and Mr. Chen Zhongji, appointed in May 2014, both bringing extensive experience in their respective fields[31] - The supervisory board is chaired by Mr. Li Tianzhong, who has been in the role since September 2010, ensuring governance and compliance within the company[33] - The company has established a set of conduct standards for directors in accordance with the listing rules[77] - The board has defined its role in guiding and leading company affairs, setting strategic directions, and establishing business development plans[80] - The company emphasizes the importance of board members having sufficient knowledge of the business and dedicating adequate time to fulfill their responsibilities[81] Employee Information - The company had a total of 6,346 employees as of December 31, 2016, with a total payroll of RMB 371.482 million[48] - The company reported a total of 2,924 retired employees as of December 31, 2016[48] - The company has a total of 1,143 employees with a university degree or higher, representing about 18% of the workforce[48] - The company completed 64 training programs in 2016, training 4,032 employees, and sent 157 employees for external training[49] - The remuneration for the highest-paid director, Zhang Daming, was RMB 824,000 in 2016[45] - The total remuneration for directors, supervisors, and senior management in 2016 amounted to RMB 8.184 million[45] Research and Development - The company is actively involved in the pharmaceutical industry, with a focus on drug development and market expansion strategies[32] - The company is committed to enhancing its research and development capabilities to drive innovation in the pharmaceutical sector[36] - The company established several research collaborations, including a joint research center with the Chinese Academy of Medical Sciences[115] - The company is focusing on technological advancements and aims to accelerate new product clinical research and international registration[120] - The group’s research and development expenses increased, contributing to a rise in management expenses by 10.75% year-on-year to RMB 335,871 thousand[130] Environmental Responsibility - The company has established three wastewater treatment facilities with a processing capacity of 12,000 tons per day, ensuring stable compliance with wastewater discharge standards[196] - The company has built three incineration facilities for hazardous waste disposal and strictly follows the transfer protocol for hazardous waste management[199] - The company has implemented a comprehensive strategy for air pollution control, including the use of closed-loop systems for gas emissions during reactions[198] - The company has adopted LDAR technology to monitor and repair VOC leak points in various containers and pipelines, controlling environmental pollution[198] - The company has been awarded the title of energy-saving advanced enterprise in Shandong Province, reflecting its commitment to environmental protection[191] Audit and Compliance - The company received a standard unqualified audit report from ShineWing Certified Public Accountants for the 2016 financial report, confirming that the financial statements accurately reflect the company's financial position as of December 31, 2016[57] - The company’s financial statements for 2016 were deemed accurate and complete by the audit committee[56] - The company has retained the auditing firm for 21 consecutive years, ensuring consistent oversight of financial reporting[90] - The company has implemented a strict insider information management system, with no violations reported during the year[189] - The company has adhered to the principles of timely and accurate information disclosure, ensuring no false records or misleading statements occurred during the reporting period[61] Future Plans - The company plans to consider distributing a special dividend after the completion of a non-public issuance of A-shares[6] - The company plans to complete the non-public issuance of A-shares, expected to raise over RMB 600 million, enhancing employee cohesion and company vitality[118] - The company is actively pursuing international project cooperation to optimize product structure and cultivate new growth points[121] - The company is enhancing its e-commerce layout, with online sales at Xinhua Pharmacy doubling and engaging in various health projects[119]
新华制药(000756) - 2017 Q1 - 季度财报
2017-04-18 16:00
Financial Performance - The company's operating revenue for Q1 2017 was CNY 1,295,383,415.66, representing a 28.91% increase compared to CNY 1,004,837,793.33 in the same period last year[8] - Net profit attributable to shareholders was CNY 51,550,425.89, a significant increase of 153.98% from CNY 20,296,756.30 year-on-year[8] - The net profit after deducting non-recurring gains and losses reached CNY 42,672,569.90, up 103.94% from CNY 20,924,190.86 in the previous year[8] - The total profit for the first quarter of 2017 was RMB 68,804,145.46, representing a growth of 131.11% year-on-year, while the net profit attributable to shareholders was RMB 51,550,425.89, up 153.98% year-on-year, driven by product technology advancements and market expansion[17] Cash Flow - The net cash flow from operating activities was CNY 54,305,762.76, reflecting a 14.35% increase from CNY 47,488,815.21 in the same quarter last year[8] - The net cash flow from investing activities for the first quarter of 2017 was RMB -100,816,810.37, a decrease of RMB 53,477,477.42 year-on-year, mainly due to increased investment in engineering projects[18] - The company reported a net cash flow from financing activities of RMB 28,857,774.10 for the first quarter of 2017, an increase of RMB 54,471,120.38 year-on-year, due to new borrowings[18] Earnings and Shareholder Information - Basic earnings per share rose to CNY 0.11, marking a 175.00% increase compared to CNY 0.04 in the previous year[8] - Total assets at the end of the reporting period were CNY 4,847,044,602.36, a 2.63% increase from CNY 4,722,785,963.84 at the end of the previous year[8] - Net assets attributable to shareholders increased to CNY 2,041,574,025.50, up 2.67% from CNY 1,988,419,824.33 at the end of the last year[8] - The company reported a weighted average return on equity of 2.56%, an increase of 1.49 percentage points from 1.07% in the previous year[8] - The total number of shareholders at the end of the reporting period was 23,150, with the top ten shareholders holding significant stakes[12] Receivables and Assets - As of March 31, 2017, the company's accounts receivable amounted to RMB 509,404,636.57, an increase of 48.34% compared to the beginning of the year, primarily due to expanded sales scale and payment terms not yet reached for some sales[17] - As of March 31, 2017, the company's notes receivable were RMB 210,835,949.09, up 97.03% from the beginning of the year, reflecting increased sales[17] - The company's other current assets decreased by 85.13% to RMB 9,460,175.78, mainly due to a reduction in VAT credits[17] - The company's prepayments decreased by 30.93% to RMB 46,547,855.36, as some prepayments were realized as sales during the reporting period[17] Expenses - The company's sales expenses for the first quarter of 2017 were RMB 152,556,515.24, an increase of 46.16% year-on-year, attributed to active market development efforts[17] - The company's tax expenses for the first quarter of 2017 totaled RMB 14,122,917.14, a rise of 125.43% year-on-year, primarily due to increased profits[18] Non-Recurring Items - Non-recurring gains and losses totaled CNY 8,877,855.99, primarily from non-current asset disposal gains and government subsidies[9] Future Plans - The company is in the process of a non-public offering of A-shares, which was approved by the China Securities Regulatory Commission on December 7, 2016, but has not yet received formal approval[19]
新华制药(000756) - 2016 Q4 - 年度财报
2017-03-14 16:00
Financial Performance - In 2016, the company's operating revenue reached RMB 4,014,963,065.74, representing an increase of 11.62% compared to RMB 3,597,033,209.79 in 2015[11]. - The net profit attributable to shareholders of the listed company was RMB 122,271,549.68, a significant increase of 47.20% from RMB 83,062,257.17 in the previous year[11]. - The total profit of the company for 2016 was RMB 159,968,492.21, which is a 35.88% increase from RMB 117,729,615.03 in 2015[11]. - The company reported a net cash flow from operating activities of RMB 439,348,332.79, which is an increase of 26.02% compared to RMB 348,636,176.12 in 2015[11]. - The basic earnings per share for 2016 were RMB 0.27, up 50.00% from RMB 0.18 in 2015[11]. Assets and Liabilities - The total assets of the company at the end of 2016 were RMB 4,722,785,963.84, reflecting a growth of 5.13% from RMB 4,492,122,436.63 at the end of 2015[11]. - The total liabilities increased by 5.40% to RMB 2,643,478,538.19 at the end of 2016, compared to RMB 2,508,040,118.23 at the end of 2015[11]. - The group's asset-liability ratio stands at 55.97%, calculated as total liabilities divided by total assets multiplied by 100%[143]. Shareholder Information - The largest shareholder, Shandong Xinhua Pharmaceutical Group Co., Ltd., holds 34.46% of the shares, totaling 157,587,763 shares[19]. - The second largest shareholder, Hong Kong Central Clearing Limited, holds 32.56% of the shares, totaling 148,883,698 shares[19]. - The total number of shareholders increased from 29,550 to 34,395 during the reporting period[18]. - The company has a total of 457,312,830 shares, with 99.998% being tradable without restrictions[19]. Corporate Governance - The company has strengthened its corporate governance, ensuring compliance with relevant laws and regulations, and maintaining effective decision-making and supervisory processes[60]. - The company has not reported any shareholdings by its directors and supervisors as of December 31, 2016, indicating a potential focus on corporate governance and transparency[39]. - The independent supervisory board includes members with legal and financial expertise, enhancing the company's governance framework[34]. - The company has established a system for accountability regarding significant errors in annual report disclosures to enhance transparency and accuracy[193]. Employee Information - The company had a total of 6,346 employees as of December 31, 2016, with a total salary expenditure of RMB 371.482 million[48]. - The total remuneration for directors, supervisors, and senior management in 2016 amounted to RMB 8.184 million[45]. - The company completed 64 training programs in 2016, training 4,032 employees, and sent 157 employees for external training[49]. Research and Development - The company is actively involved in the pharmaceutical industry, with a commitment to research and development, as evidenced by the qualifications of its management team[32]. - The company successfully passed 141 audits, including a zero-defect inspection by the US FDA for 14 products[115]. - The company established several research collaborations, including a joint research center with the Chinese Academy of Medical Sciences[115]. Market Performance - Revenue from chemical raw materials grew by 19.79%, while revenue from formulation industry increased by 7.85%[114]. - The sales revenue of chemical raw materials reached RMB 1,770,296,000, up 19.79% from the previous year[127]. - The sales revenue of formulation products was RMB 1,747,611,000, an increase of 5.36% year-on-year[127]. Compliance and Auditing - The company received a standard unqualified audit report from ShineWing Certified Public Accountants for the 2016 financial report, confirming that the financial statements accurately reflect the company's financial position as of December 31, 2016[57]. - The company's financial statements for 2016 were deemed accurate and compliant with accounting standards by the audit committee[56]. - The internal control audit report issued by the accounting firm indicates that the company maintained effective financial reporting internal controls as of December 31, 2016[72]. Future Plans - The company plans to consider distributing a special dividend after the completion of a non-public issuance of A shares[6]. - The company plans to complete a non-public offering of A-shares, expected to raise over RMB 600 million, enhancing employee cohesion and company vitality[118]. - The company is actively pursuing international project cooperation and product international registration to enhance growth[120].
新华制药(000756) - 2016 Q3 - 季度财报
2016-10-26 16:00
Financial Performance - Net profit attributable to shareholders was ¥43,313,070.81, reflecting a growth of 20.58% year-on-year[8]. - Operating revenue for the period was ¥977,969,739.89, representing an 18.55% increase compared to the same period last year[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥33,804,998.20, up 37.45% year-on-year[8]. - Basic earnings per share increased by 12.50% to ¥0.09[8]. - The weighted average return on equity rose by 0.31 percentage points to 2.24%[8]. - For the first nine months of 2016, total profit reached RMB 123,593,529.93, representing a 34.09% increase year-on-year, driven by product technology improvements and expanded marketing efforts[18]. - Investment income for the first nine months of 2016 was RMB 7,781,048.82, up 48.75% year-on-year, attributed to increased dividend income from available-for-sale financial assets[18]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,599,789,506.27, an increase of 2.40% compared to the end of the previous year[8]. - As of September 30, 2016, accounts receivable amounted to RMB 480,875,304.06, an increase of 52.98% compared to the beginning of the year, primarily due to the payment terms of certain sales not yet being due[17]. - The company's construction in progress as of September 30, 2016, was RMB 341,037,838.40, a significant increase of 119.56% from the beginning of the year, due to increased investment in key projects[17]. - Other current assets decreased by 65.64% to RMB 7,240,056.67, mainly due to a reduction in the value-added tax receivable[17]. - The company's long-term borrowings decreased by 73.56% to RMB 100,000,000.00, as part of the long-term debt was reclassified to current liabilities[17]. - The company reported a decrease in accounts payable by 51.98% to RMB 103,544,527.94, primarily due to the repayment of due notes[17]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥241,910,554.24, an increase of 19.62% compared to the previous year[8]. - The net cash flow from investing activities for the first nine months of 2016 was RMB -126,644,230.65, a decrease of RMB 40,638,689.82 compared to the same period last year[18]. Shareholder Information - The total number of shareholders at the end of the reporting period was 39,475[12]. - The largest shareholder, Shandong Xinhua Pharmaceutical Group Co., Ltd., holds 34.46% of the shares[12]. - The company did not engage in any repurchase transactions during the reporting period[14]. Tax and Interest Obligations - The company's interest payable increased significantly by RMB 28,980,892.72 to RMB 30,187,233.83, primarily due to interest payments on long-term borrowings at year-end[17]. - The company's tax payable increased by 37.77% to RMB 22,683,208.09, mainly due to higher value-added tax and urban construction tax obligations[17].
新华制药(000756) - 2016 Q2 - 季度财报
2016-08-29 16:00
Financial Performance - The company's operating revenue for the first half of 2016 was CNY 1,998,500,412.91, representing a 2.57% increase compared to CNY 1,948,408,051.58 in the same period last year[13]. - The total profit for the period was CNY 67,886,265.86, a significant increase of 52.63% from CNY 44,479,116.56 year-on-year[13]. - Net profit attributable to shareholders of the listed company reached CNY 45,867,145.68, marking a 77.37% increase from CNY 25,859,577.55 in the previous year[13]. - The net cash flow from operating activities was CNY 83,830,656.73, up 14.41% from CNY 73,271,923.37 in the same period last year[13]. - The basic earnings per share increased to CNY 0.10, up 66.67% from CNY 0.06 in the same period last year[13]. - Operating profit increased significantly by 70.53% to RMB 68,650,000, driven by cost reduction efforts and market expansion[46]. - The total operating costs for the first half of 2016 were CNY 1,929,863,877.24, a slight increase of 0.99% from CNY 1,910,857,985.72[75]. Assets and Liabilities - The company's total assets as of June 30, 2016, were CNY 4,387,046,443.24, a decrease of 2.34% from CNY 4,492,122,436.63 at the end of the previous year[13]. - Total liabilities decreased by 4.71% to CNY 2,389,856,720.53 from CNY 2,508,040,118.23 at the end of the previous year[13]. - The asset-liability ratio was 54.48% as of June 30, 2016, reflecting a stable financial structure[43]. - The total current assets as of June 30, 2016, amounted to RMB 1,518,610,515.26, a decrease from RMB 1,651,479,267.05 at the beginning of the year, reflecting a decline of approximately 8.04%[67]. - Cash and cash equivalents decreased from RMB 476,288,884.09 to RMB 403,202,882.31, representing a decline of about 15.36%[67]. - Accounts receivable increased from RMB 314,348,372.90 to RMB 432,153,263.28, marking an increase of approximately 37.50%[67]. - Inventory decreased from RMB 546,460,168.40 to RMB 443,218,403.27, indicating a reduction of about 18.93%[67]. Shareholder Information - The total number of shareholders as of June 30, 2016, was 30,303, including 46 H-share shareholders and 30,257 A-share shareholders[18]. - The largest shareholder is Shandong Xinhua Pharmaceutical Group Co., Ltd., holding 157,587,763 shares, which accounts for 34.46% of the total shares[19]. - The second largest shareholder is Hong Kong Central Clearing (Agent) Co., Ltd., with 148,883,698 shares, representing 32.56%[19]. - The top ten shareholders collectively hold a significant portion of the company's shares, with the smallest among them, New Era Securities, holding 1,416,077 shares, or 0.31%[19]. - As of June 30, 2016, there were no changes in the controlling shareholders or actual controllers of the company[23]. Governance and Management - The company has maintained a stable governance structure with no changes in key management personnel during the reporting period[27]. - The company does not provide remuneration or allowances to its directors and senior management from shareholder units[28]. - The company has not disclosed any relationships or concerted actions among the top ten shareholders[22]. Research and Development - The company obtained 6 patent authorizations in the first half of 2016, including 2 invention patents[35]. - Research and development investment decreased by 35.78% to RMB 39,983,826.82 due to reduced input in certain projects during the first half of the year[45]. - The company plans to launch 8 raw materials and 12 formulation new products for clinical research in the second half of 2016[38]. Cash Flow and Financing - The company reported a net decrease in cash and cash equivalents of RMB 266,393,000, primarily due to reduced cash inflow from financing activities[46]. - The company's total bank borrowings amounted to RMB 757,400 thousand as of June 30, 2016[42]. - Cash inflow from operating activities totaled RMB 776,969,698.23, up from RMB 633,137,141.42, representing an increase of about 22.7%[81]. - Cash outflow from operating activities increased significantly to RMB 814,276,201.48 from RMB 540,414,525.31, marking an increase of approximately 50.5%[81]. Government Grants and Subsidies - The company has ongoing projects related to environmental protection and pharmaceutical innovation, with specific government grants allocated for these initiatives[198]. - The company is actively involved in technology innovation projects, with several government subsidies aimed at enhancing its research and development capabilities[199]. - The total amount of government subsidies recognized in the current period was ¥1.65 million, with a remaining balance of ¥100.6 million at the end of the period[197]. Financial Reporting and Compliance - The company adheres to the Chinese Accounting Standards, ensuring that the financial statements accurately reflect the financial position and operating results as of June 30, 2016[99]. - The financial statements are prepared based on the going concern assumption, indicating a history of profitable operations and financial resources to support ongoing activities[98]. - The company has no changes in significant accounting policies or estimates during the current period[154][155].
新华制药(000756) - 2016 Q1 - 季度财报
2016-04-29 16:00
Financial Performance - The company's operating revenue for Q1 2016 was CNY 1,004,837,793.33, representing a 0.53% increase compared to CNY 999,523,085.35 in the same period last year[8]. - Net profit attributable to shareholders was CNY 20,296,756.30, a significant increase of 42.34% from CNY 14,259,441.26 year-on-year[8]. - The net profit after deducting non-recurring gains and losses reached CNY 20,924,190.86, marking a 61.96% increase from CNY 12,919,419.71 in the previous year[8]. - The total profit for the first quarter of 2016 was RMB 29,771,675.55, representing a growth of 42.43% year-on-year, mainly due to ongoing product technology improvements and reduced procurement costs[18]. Cash Flow and Assets - The net cash flow from operating activities improved to CNY 47,488,815.21, a remarkable increase of 361.68% compared to a negative cash flow of CNY -18,147,578.63 in the same period last year[8]. - The net cash flow from operating activities for the first quarter of 2016 was RMB 47,488,815.21, an increase of RMB 65,636,393.84 compared to the same period last year, attributed to enhanced fund management and improved profitability[19]. - Total assets at the end of the reporting period were CNY 4,506,695,596.48, reflecting a 0.32% increase from CNY 4,492,122,436.63 at the end of the previous year[8]. - The company's accounts receivable amounted to RMB 476,752,183.87, an increase of 51.66% compared to the beginning of the year, primarily due to the payment terms of some sales not being reached[17]. - The company's interest receivables as of March 31, 2016, were RMB 2,885,767.79, up 48.92% from the beginning of the year, due to increased interest income from bank deposits[17]. - The company's construction in progress was RMB 206,442,918.13, an increase of 32.91% compared to the beginning of the year, reflecting ongoing investment in engineering projects[17]. Shareholder Information - The total number of shareholders at the end of the reporting period was 33,715[12]. - The largest shareholder, Shandong Xinhua Pharmaceutical Group Co., Ltd., held a 34.46% stake, amounting to 157,587,763 shares[12]. Liabilities and Taxation - The company's tax payable as of March 31, 2016, was RMB 37,089,813.61, an increase of 125.27% from the beginning of the year, primarily due to a significant rise in payable VAT[17]. - The company's deferred tax liabilities were RMB 6,803,607.59, a decrease of 32.12% from the beginning of the year, due to a temporary decline in the fair value of available-for-sale financial assets[17]. Other Financial Activities - The company's investment income for the first quarter of 2016 was RMB 12,916.67, a decrease of 94.20% year-on-year, mainly due to a reduction in structured deposit amounts compared to the previous year[19]. - The company's prepayments as of March 31, 2016, were RMB 28,140,317.97, a decrease of 30.42% from the beginning of the year, as some prepayments were recognized as sales during the reporting period[17]. - The company did not conduct any repurchase transactions among its top 10 shareholders during the reporting period[14]. - No research, communication, or interview activities were conducted during the reporting period[26]. - There were no instances of non-compliant external guarantees during the reporting period[27]. - There were no non-operating fund occupations by controlling shareholders or their affiliates during the reporting period[28].
新华制药(000756) - 2015 Q4 - 年度财报
2016-03-30 16:00
Financial Performance - The total operating revenue for 2015 was approximately CNY 3.60 billion, representing a year-on-year increase of 0.20% compared to CNY 3.59 billion in 2014[13]. - The net profit for 2015 reached approximately CNY 94.01 million, a significant increase of 37.57% from CNY 68.33 million in 2014[13]. - The basic earnings per share for 2015 was CNY 0.18, reflecting a growth of 63.64% compared to CNY 0.11 in 2014[13]. - The company reported a significant increase in net profit excluding non-recurring gains and losses, which reached approximately CNY 40.94 million, a 366.42% increase from CNY 8.78 million in 2014[13]. - The company's operating profit for 2015 was RMB 92,068,000, reflecting a growth of 68.75% year-over-year, driven by high-value product sales and cost control measures[118]. - The company's revenue for the year ended December 31, 2015, was RMB 3,597,033 thousand, representing a growth of 0.20% compared to 2014[100]. - The net profit attributable to shareholders for the same period was RMB 83,062 thousand, an increase of 63.75% year-over-year[100]. - The gross profit margin for the overall business was 23.26%, with a slight increase of 2.79% compared to the previous year[121]. Assets and Liabilities - The total assets as of the end of 2015 amounted to approximately CNY 4.49 billion, an increase of 5.82% from CNY 4.25 billion at the end of 2014[13]. - The total liabilities at the end of 2015 were approximately CNY 2.51 billion, which is a 7.49% increase from CNY 2.33 billion in 2014[13]. - The total assets reached RMB 4,492,122,436.63, up from RMB 4,245,149,713.77, which is an increase of about 5.8%[196]. - The company's total liabilities grew to RMB 2,508,040,118.23 from RMB 2,333,280,726.09, indicating an increase of around 7.5%[196]. - The asset-liability ratio of the group is 55.83%[127]. Shareholder Information - The company plans to distribute a cash dividend of CNY 0.20 per 10 shares to all shareholders, pending approval at the annual general meeting[7]. - The proposed final dividend for 2015 is RMB 0.2 per 10 shares, totaling RMB 9,146,256.6, which is 11.01% of the net profit attributable to shareholders[156]. - As of December 31, 2015, the total number of shareholders was 32,257, which increased to 34,123 by February 29, 2016[21]. - The largest shareholder, Shandong Xinhua Pharmaceutical Group, held 34.46% of the shares, totaling 157,587,763 shares[22]. Corporate Governance - The company continues to strengthen corporate governance and ensure compliance with laws and regulations[61]. - The board of directors includes experienced professionals with backgrounds in economics, medicine, and engineering, contributing to the company's strategic direction[29][30]. - The company has established an independent accounting system and financial management procedures, ensuring compliance with relevant regulations[59]. - The audit committee confirmed that the financial statements for 2015 were prepared in accordance with accounting policies and accurately reflected the company's financial position[56]. - The company has established a robust internal control system, which has been effectively executed without any significant deficiencies[86]. Employee Information - As of December 31, 2015, the total number of employees in the group was 6,348, with a total salary expenditure of RMB 324.158 million[47]. - The employee distribution by function includes 3,511 production personnel, 1,060 sales personnel, and 603 engineering technicians[48]. - The total annual remuneration for directors, supervisors, and senior management in 2015 amounted to RMB 6.271 million[44]. Research and Development - Research and development expenditure rose to RMB 117,846,000, an increase of 38.91% from the previous year, accounting for 3.28% of operating revenue[120]. - The company aims to enhance its international strategy by promoting product exports and international cooperation in product development and market expansion[107]. - The company achieved 22 patent grants during the year, including 15 invention patents[102]. Market and Sales Performance - The sales revenue of the formulation segment reached RMB 1.3 billion, an increase of 17.3% year-on-year, with the segment accounting for 46.1% of total sales, up by 2.0 percentage points[101]. - The sales of formulation products increased by 4.69% to RMB 1,658,771,000, benefiting from strategic product adjustments[113]. - The company is focusing on expanding its retail pharmacy and hospital market presence through e-commerce and traditional sales channels[105]. Compliance and Transparency - The company has established a system for accountability regarding significant errors in annual report disclosures, ensuring transparency and accuracy[176]. - The company actively engages in investor relations, ensuring timely and accurate information disclosure to enhance transparency[84]. - The independent non-executive directors confirmed their independence in accordance with the relevant listing rules[73].